Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.
A new immunotherapy combination restored responses in advanced bladder cancer patients who had failed previous treatments.
The Phase I-II ICRA trial demonstrated 26% objective response with paclitaxel plus high-dose anti-CTLA-4 (tremelimumab) in therapy-refractory metastatic urothelial carcinoma after platinum and ICI failure (n=44, Netherlands Cancer Institute). Transcriptomic data suggest chemotherapy-induced immune induction that may restore checkpoint sensitivity in this difficult-to-treat population.
What the study was
- Study design
- Phase I/II randomized clinical trial (multicenter, open-label)
- Population
- Metastatic urothelial carcinoma patients post-platinum chemotherapy and ICI, n=44
- Sample size
- 44
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nat Commun
Why it surfaced
Phase I-II trial showing 26% ORR in a difficult-to-treat population (ICI-refractory mUC) with paclitaxel + anti-CTLA-4. Supports concept of immune re-sensitization after ICI failure. Small n limits interpretation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.